Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J. Kuter, Hanny Al-Samkari, James B. Bussel, Marie Godar, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian C. Newland

Blood (2022) 140 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2022-167838

Published: 2022

Journal Articles

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

Eun-Ju Lee, Marina Beltrami-Moreira, Hanny Al-Samkari, Adam Cuker, Jennifer DiRaimo, Terry Gernsheimer, Alexandra Kruse, Craig Kessler, Caroline Kruse, Andrew D. Leavitt, Alfred I. Lee, Howard A. Liebman, Adrian C. Newland, Ashley E. Ray, Michael D. Tarantino, Jecko Thachil, David J. Kuter, Douglas B. Cines, James B. Bussel

Blood (2022) 139 (10): 1564–1574.

https://doi.org/10.1182/blood.2021013411

Published: 2022

Includes: Supplemental data

Journal Articles

How Effective Are the Immunosuppressive Therapies Rituximab and Mycophenolate Mofetil in Immune Thrombocytopenia? Real World Evidence from the UK ITP Registry

Vickie McDonald, Gerorge Loughlin, Andrew Laws, Duncan Stacey, Jeffrey Spears, Atiqa Miah, Haroon Miah, Quentin Hill, Nichola Cooper, Michael Makris, Charlotte Bradbury, Adrian C. Newland

Blood (2021) 138 (Supplement 1): 1016.

https://doi.org/10.1182/blood-2021-152650

Published: 2021

Journal Articles

Romiplostim for the Treatment of Adult Patients with Newly Diagnosed or Persistent Immune Thrombocytopenia: Subgroup Analysis from a Phase 2 Study

Adrian C. Newland, Jean-Francois Viallard, María Fernanda López Fernández, Melissa Jeanne Eisen, Hossam A Saad, Jane Hippenmeyer, Bertrand Godeau

Blood (2021) 138 (Supplement 1): 3157.

https://doi.org/10.1182/blood-2021-150257

Published: 2021

Journal Articles

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia

Eun-Ju Lee, Marina Beltrami Moreira, Hanny Al-Samkari, Adam Cuker, Jennifer MacWhirter - DiRaimo, Terry B. Gernsheimer, Alexandra Kruse, Craig M. Kessler, Caroline Kruse, Andrew D Leavitt, Alfred Ian Lee, Howard A. Liebman, Adrian C. Newland, Ashley E. Ray, Michael D Tarantino, Jecko Thachil, David J. Kuter, Douglas B. Cines, James B Bussel

Blood (2021) 138 (Supplement 1): 586.

https://doi.org/10.1182/blood-2021-152918

Published: 2021

Journal Articles

Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

Adrian C. Newland, Howard A. Liebman, MD, Vickie McDonald, MD, Marc Michel, Yoshitaka Miyakawa, Wim Parys, MD, Hans De Haard, Peter Ulrichts, Marie Godar, Kristof De Beuf, Jaume Ayguasanosa, Catherine M Broome, David J. Kuter, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141161

Published: 2020

Journal Articles

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Adrian C. Newland, Blanca Sánchez-González, László Rejtő, Miklos Egyed, Nataliya Romanyuk, Marie Godar, Katrien Verschueren, Domenica Gandini, Peter Ulrichts, Jon Beauchamp, Torsten Dreier, E. Sally Ward, Marc Michel, Howard A. Liebman, Hans De Haard, Nicolas Leupin, David J. Kuter

Blood (2019) 134 (Supplement_1): 895.

https://doi.org/10.1182/blood-2019-128022

Published: 2019

Journal Articles

Differential and tumor-specific expression of CD160 in B-cell malignancies

Timothy W. Farren, Jerome Giustiniani, Feng-Ting Liu, Dimitris A. Tsitsikas, Marion G. Macey, James D. Cavenagh, Heather E. Oakervee, David Taussig, Adrian C. Newland, Maria Calaminici, Armand Bensussan, Michael Jenner, John G. Gribben, Samir G. Agrawal

Blood (2011) 118 (8): 2174–2183.

https://doi.org/10.1182/blood-2011-02-334326

Published: 2011

Includes: Supplemental data

Journal Articles

International consensus report on the investigation and management of primary immune thrombocytopenia

Blood (2010) 115 (2): 168–186.

https://doi.org/10.1182/blood-2009-06-225565

Published: 2010

Includes: Supplemental data

Journal Articles

Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib

Feng-Ting Liu, Samir G. Agrawal, Zanyar Movasaghi, Peter B. Wyatt, Ihtesham U. Rehman, John G. Gribben, Adrian C. Newland, Li Jia

Blood (2008) 112 (9): 3835–3846.

https://doi.org/10.1182/blood-2008-04-150227

Published: 2008

Includes: Supplemental data

Journal Articles

Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia

Samir G. Agrawal, Feng-Ting Liu, Catherine Wiseman, Sima Shirali, Hongxiang Liu, Debra Lillington, Ming-Qing Du, Denise Syndercombe-Court, Adrian C. Newland, John G. Gribben, Li Jia

Blood (2008) 111 (5): 2790–2796.

https://doi.org/10.1182/blood-2007-10-110460

Published: 2008

Journal Articles

Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL

Feng-Ting Liu, Samir G. Agrawal, John G. Gribben, Hongtao Ye, Ming-Qing Du, Adrian C. Newland, Li Jia

Blood (2008) 111 (5): 2797–2805.

https://doi.org/10.1182/blood-2007-08-110445

Published: 2008

Journal Articles

Universal CD160 Expression and the CD5+23+ / CD5+19+ Ratio in Chronic Lymphocytic Leukemia Simplfy Identification of Atypical Cases from CD23+ Mantle Cell Lymphoma.

Dimitris A. Tsitsikas, Jerrome Giustiniani, Anne Skipper, Fatema Ebrahim, Ulrika Johannson, Marion Macey, Michael Jenner, Adrian C. Newland, Samir G. Agrawal

Blood (2007) 110 (11): 4678.

https://doi.org/10.1182/blood.V110.11.4678.4678

Published: 2007

Journal Articles

Bax Degradation Activity Is a Novel Poor Prognosis Marker of Chronic Lymphocytic Leukemia.

Samir G. Agrawal, MD, PhD, Feng-Ting Liu, MB, PhD, Catherine Wiseman, PhD, Sima Shirali, PhD, Hongxiang Liu, PhD, Debra Lillington, PhD, Ming Qing Du, MB, PhD, Denise Syndercombe Court, PhD, Adrian C. Newland, MD, John G. Gribben, MD, PhD, Li Jia, MB, PhD

Blood (2007) 110 (11): 3087.

https://doi.org/10.1182/blood.V110.11.3087.3087

Published: 2007

Journal Articles

GCS-100, a Galectin 3 Antagonist, Is a Novel Caspase-9 Apoptosis Activating Agent for the Treatment of Indolent B-Cell Malignancies.

Finbarr E. Cotter, MD PhD, Bo Su, MD, Margherita Corbo, BSc, Y. Chang, Joanne Schindler, Brad Carver, Christopher D. Fegan, MD, Adrian C. Newland, MD, Rebecca L. Auer, MD PhD

Blood (2004) 104 (11): 3286.

https://doi.org/10.1182/blood.V104.11.3286.3286

Published: 2004

Journal Articles

Comparison of rHuEpo plus rHuG-CSF and supportive care: apples to oranges

Roberto Stasi, Sergio Amadori, Adrian C. Newland, Drew Provan

Blood (2004) 104 (7): 2201–2202.

https://doi.org/10.1182/blood-2004-04-1334

Published: 2004

Journal Articles

Apaf-1 protein deficiency confers resistance to cytochrome c –dependent apoptosis in human leukemic cells

Li Jia, Srinivasa M. Srinivasula, Feng-Ting Liu, Adrian C. Newland, Teresa Fernandes-Alnemri, Emad S. Alnemri, Stephen M. Kelsey

Blood (2001) 98 (2): 414–421.

https://doi.org/10.1182/blood.V98.2.414

Published: 2001

Journal Articles

Subcellular Distribution and Redistribution of Bcl-2 Family Proteins in Human Leukemia Cells Undergoing Apoptosis

Li Jia, Marion G. Macey, Yuzhi Yin, Adrian C. Newland, Stephen M. Kelsey

Blood (1999) 93 (7): 2353–2359.

https://doi.org/10.1182/blood.V93.7.2353

Published: 1999

Journal Articles

Modulation of Idarubicin-Induced Apoptosis in Human Acute Myeloid Leukemia Blasts by All-Trans Retinoic Acid, 1,25(OH) 2 Vitamin D3, and Granulocyte-Macrophage Colony-Stimulating Factor

Nicolas J. Ketley, Paul D. Allen, Stephen M. Kelsey, Adrian C. Newland

Blood (1997) 90 (11): 4578–4587.

https://doi.org/10.1182/blood.V90.11.4578

Published: 1997

NARROW

Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

How Effective Are the Immunosuppressive Therapies Rituximab and Mycophenolate Mofetil in Immune Thrombocytopenia? Real World Evidence from the UK ITP Registry

Romiplostim for the Treatment of Adult Patients with Newly Diagnosed or Persistent Immune Thrombocytopenia: Subgroup Analysis from a Phase 2 Study

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia

Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Differential and tumor-specific expression of CD160 in B-cell malignancies

International consensus report on the investigation and management of primary immune thrombocytopenia

Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib

Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia

Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL

Universal CD160 Expression and the CD5+23+ / CD5+19+ Ratio in Chronic Lymphocytic Leukemia Simplfy Identification of Atypical Cases from CD23+ Mantle Cell Lymphoma.

Bax Degradation Activity Is a Novel Poor Prognosis Marker of Chronic Lymphocytic Leukemia.

GCS-100, a Galectin 3 Antagonist, Is a Novel Caspase-9 Apoptosis Activating Agent for the Treatment of Indolent B-Cell Malignancies.

Comparison of rHuEpo plus rHuG-CSF and supportive care: apples to oranges

Apaf-1 protein deficiency confers resistance to cytochrome c –dependent apoptosis in human leukemic cells

Subcellular Distribution and Redistribution of Bcl-2 Family Proteins in Human Leukemia Cells Undergoing Apoptosis

Modulation of Idarubicin-Induced Apoptosis in Human Acute Myeloid Leukemia Blasts by All-Trans Retinoic Acid, 1,25(OH) 2 Vitamin D3, and Granulocyte-Macrophage Colony-Stimulating Factor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only